Elan secures restricted Tysabri approval

Irish-based multinational pharmaceutical giant Elan and Nasdaq-quoted Biogen Idec have been given restricted approval by the US Food and Drug Administration (FDA) for the reintroduction of multiple sclerosis drug Tysabri.

Shares in Elan fell by 70% in just one day's trading when the multiple sclerosis 'wonder drug' was withdrawn last year due to major fears about its safety.